• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, February 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Lyncean Technologies Inc. closes $13.75 million funding with a syndicate including Intel Capital

Bioengineer by Bioengineer
May 8, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

FREMONT, CA — Lyncean Technologies, a pioneer in compact accelerator-based light sources for use in industry and academia, has secured $13.75 million in the initial close of a Series B financing round with a syndicate including Intel Capital. The round included participation from current investors EuroUS Ventures AG, Anchor Fund and Quintus Vermoegensverwaltung GmbH. The investment will support development of a novel high power extreme ultraviolet (EUV) source for potential future use in semiconductor manufacturing. Lyncean also will expand manufacturing operations for its Compact Light Source (CLS), a high flux X-ray source that makes synchrotron quality experiments possible in a local laboratory.

"The funding provided by this group of investors reinforces our vision of the Compact Light Source changing the landscape of applied research," said Michael Feser, CEO of Lyncean Technologies. "This new round also enables initial development of an accelerator-based, clean, reliable, high power EUV source for potential use in future lithography systems."

Lyncean Technologies will use the investment to install a Compact Light Source for customer demonstration purposes and to make required personnel investments to develop the EUV source.

"Our investment will help Lyncean grow its business and develop its extreme ultraviolet technology," said Wendell Brooks, senior vice president of Intel Corporation and president of Intel Capital. "We are glad to support innovative approaches to semiconductor manufacturing that support the continuation of Moore's Law."

###

About Lyncean Technologies

Lyncean Technologies, Inc. was founded in 2001 to develop the Compact Light Source (CLS), a miniature synchrotron X-ray source based on research performed at the SLAC National Accelerator Laboratory and Stanford University. The CLS replaces the conventional "undulator" magnets in large synchrotrons via laser technology, which scales down the entire device by a factor of 200 to provide industrial and academic customers a home solution for state-of-the-art X-ray needs. Lyncean's newest development is a novel EUV source based on coherent photon generation in a compact electron storage ring, specifically designed for high volume manufacturing semiconductor lithography. For more information visit: http://www.lynceantech.com

About Intel Capital

Intel Capital invests in innovative startups targeting artificial intelligence, autonomous driving, workload accelerators, 5G connectivity, virtual reality and a wide range of other disruptive technologies. Since 1991, Intel Capital has invested $12.3 billion in 1,530 companies worldwide, and more than 660 portfolio companies have gone public or been acquired. Intel Capital curates thousands of business development introductions each year between its portfolio companies and the Global 2000. For more information on what makes Intel Capital one of the world's most powerful venture capital firms, visit http://www.intelcapital.com or follow @Intelcapital.

Media Contact

Jack Kasahara
[email protected]
408-838-6034

http://www.lynceantech.com

Share12Tweet7Share2ShareShareShare1

Related Posts

Evaluating Pediatric Emergency Care Quality in Ethiopia

February 7, 2026

TPMT Expression Predictions Linked to Azathioprine Side Effects

February 7, 2026

Improving Dementia Care with Enhanced Activity Kits

February 7, 2026

Decoding Prostate Cancer Origins via snFLARE-seq, mxFRIZNGRND

February 7, 2026
Please login to join discussion

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    57 shares
    Share 23 Tweet 14
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Evaluating Pediatric Emergency Care Quality in Ethiopia

TPMT Expression Predictions Linked to Azathioprine Side Effects

Improving Dementia Care with Enhanced Activity Kits

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.